References
- Pesta M, Topolcan O, Holubec L, Rupert K, Cerna M, Holubec L, et al. Clinicopathological assesment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007; 27: 1863-8.
- Li M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metaloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth and angiogenesis. Exp Biol Med 2006; 231: 20-7.
- Giaginis C, Nikiteas N, Margeli A, Tzanakis N, Rallis G, Kouraklis G, et al. Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: association with clinicopathological variables and patients survival. Int J Biol Markers 2009; 24: 245-52.
- Alo-Aho R, Kahari VM. Colagenases in cancer. Biochemie 2005; 87: 273-86.
- Sørensen NM, Sørensen IV, Wűrtz SØ, Schrohl AS, Dowell B, Davis G, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scan J Gastroenterol 2008; 43: 774-86.
- Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, et al. Assesment of the biological variation of plasma tissue inhibitor of metalloproteinase-1. Int J Biol Markers 2008; 23: 42-7.
- Horvat M, Stabuc B. Microsatellite instability in colorectal cancer. Radiol Oncol 2011; 45: 75-81.
- Yaolin Zhou Y, Boardman LA, Miller RC. Genetic testing for young-onset colorectal cancer: case report and evidence-based clinical guidelines. Radiol Oncol 2010; 44: 57-61.
- Wass ET, Hendriks T, Lomme RM, Woblles T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005; 48: 700-10.
- Kahlert C, Bandapalli OR, Schirmacher P, Weitz J, Brand K. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer. Anticancer Res 2008; 28: 1459-66.
- Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80: 495-503.
- Hammer JH, Basse L, Svendsen MN, Werther K, Brüner N, Christensen IJ, et al. Impact of elective resection on plasma TIMP-1 in patients with colon cancer. Colorectal Dis 2006; 8: 168-72.
- Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156-64.
- Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292-9.
- Sofic A, Beslic S, Kocijancic I, Sehovic N. CT colonography in detection of colorectal carcinoma. Radiol Oncol 2010; 44: 19-23.
- Oblak I, Petric P, Anderluh F, Velenik V, Hudej R, Fras AP. Anal cancer chemoirradiation with curative intent - a single institution experience. Neoplasma 2009; 56: 150-5.
- Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today 2003; 33: 885-92.
- Tayebjee MH, Lip GYH, Blann AD, MacFadyen RJ. Effects of age, gender, ethnicity, diurnal variations and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 2005; 115: 205-10.